Dec 23, 2019 16:00:00

Taking a small amount of LSD for treatment of depression proves safe for 'microdose'

By

Activedia

Clinical trials have demonstrated the safety of ' microdose ', which involves taking small amounts of hallucinogens regularly using LSD.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers | SpringerLink
https://link.springer.com/article/10.1007/s00213-019-05417-7

Eleusis Announces Phase 1 Trial Results of Lysergic Acid Diethylamide (LSD) in Healthy Older Volunteers, Potential to Evaluate as Disease Modifying Therapy for Alzheimer's Disease — Eleusis
https://www.eleusisltd.com/news/2019/12/18/eleusis-announces-phase-1-trial-results-of-lysergic-acid-diethylamide-lsd-in-healthy-older-volunteers-potential- to-evaluate-as-disease-modifying-therapy-for-alzheimers-disease

Microdosing LSD for Alzheimer's proves safe in early human trial
https://newatlas.com/science/microdosing-lsd-alzheimers-phase1-trial-results-safety/

'Microdose' is a treatment that improves depression by taking small doses of hallucinogens such as LSD and magic mushrooms on a regular basis. In the United States, hallucinogens are banned by law, but many report improvements in depression and cognitive abilities.

What is 'LSD microdose' that improves creativity and depression by taking a small amount of LSD? -GIGAZINE

Previous studies have suggested that the active ingredient '

silocibin ' of Magic Mushroom , a type of hallucinogen, stimulates serotonin receptors in the brain to improve depression . On November 27, 2019, a treatment for depressive disorder (MDD) using psilocybin has been granted a breakthrough treatment designation by the US Food and Drug Administration (FDA) .

The same hallucinogen component as Magic Mushroom is approved by authorities as a `` breakthrough treatment '' for depression-gigazine

by Shutterbug75

This study evaluates the 'safety' of microdose using LSD. Research company on life sciences Eleusis , to the elderly volunteers 48 people of average age 62.9 years old, and only a small amount of LSD 5μg, 10μg, 20μg of each, for the placebo placebo was administered a total of six times every four days .

After the experiment, in addition to physical tests such as blood pressure, heart rate, and electrocardiogram, mental tests such as deep sensation , psychological calmness, cognitive ability, and psychological response were performed. 'Even though the placebo and LSD groups reported different numbers of headaches, no adverse effects were detected in any dose of LSD in safety and tolerability ,' Eleusis said. Has announced.

There is controversy over the efficacy of microdosing of LSD. A study conducted at the University of Chicago in early 2019 concluded that 'low doses of LSD do not affect mood, cognitive, or physiological measurements.' On the other hand, by the United Kingdom research institutions such as the University of London study , the subjects were administered the LSD of the trace has been shown to be referred to as 'estimate increase the length of time' consistently. These results suggest the possibility that 'when a small amount of LSD is administered, it is affected cognitively even without the awareness that it was administered.'